Clinical DevelopmentSanofiCambridge, Massachusetts, United States
OC 13.3 - Pooled Analysis of the Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients With Previously Treated Immune Thrombocytopenia: Phase 2 Study
Sunday, June 23, 202410:00 – 10:15 ICT
